================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

                Date of Report (Date of earliest event reported):
                                 January 1, 2008


                               TRANSGENOMIC, INC.
             ------------------------------------------------------
             (Exact name of registrant as specified in its charter)


       Delaware                      000-30975                   911789357
------------------------      ----------------------      ----------------------
(State of Incorporation)     (Commission File Number)         (IRS Employer
                                                          Identification Number)


  12325 Emmet Street, Omaha, Nebraska                              68164
 --------------------------------------                   ----------------------
(Address of principal executive offices)                        (Zip Code)


                                 (402) 452-5400
              ----------------------------------------------------
              (Registrant's telephone number, including area code)


                                 Not applicable
      ---------------------------------------------------------------------
          (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

|_|   Written communications pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

|_|   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))

================================================================================


Item 5.02 Election of Director.

      On January 1, 2008, the Registrant's Board of Directors appointed David P.
Pauluzzi to serve as a Class III Director. Mr. Pauluzzi has not been appointed
to any committees of the Board of Directors at this time. There are no family
relationships between Mr. Pauluzzi and any other director or executive officer
of the Registrant and he was not selected by the Board of Directors to serve as
a Director pursuant to any arrangement or understanding with any person. Mr.
Pauluzzi has not engaged in any transaction with the Registrant that would be
reportable as a related party transaction under the rules of the SEC.


Item 9.01 Financial Statements and Exhibits.

      99.1 Press Release, dated February 5, 2008, announcing the appointment of
David P. Pauluzzi to the Registrant's Board of Directors.


                                   SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.


Dated:  February 5, 2008                 TRANSGENOMIC, INC.


                                         By: /s/ Debra A. Schneider
                                             -----------------------------------
                                             Debra A. Schneider
                                             Chief Financial Officer